Pharmacogenetics of obstetric therapeutics

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Obstetric pharmacology, in many respects, is still in its infancy. Because of valid concerns about the safety of drugs to both the mother and developing fetus, not as much data exist for drugs in pregnancy. There is also a distinct paucity of data regarding pharmacogenetics in pregnancy. At this time, many of the potential pharmacogenetic applications to pregnancy drug therapy are theoretical. This chapter summarizes the drug therapy for five of the major pregnancy conditions/complications, along with a brief discussion of potential pharmacogenetic or individualized pharmacotherapy applications for each. These conditions are preterm labor, depression, diabetes, the nausea and vomiting of pregnancy (NVP), and hypertension. Preterm Labor Preterm birth is the leading cause of morbidity and mortality in newborns in the United States. More than 12.5 percent of all live births are preterm, accounting for a large amount of health care spending for infants. The number of preterm births in the United States, as well as in many other industrialized countries, continues to rise. Preterm labor is the most common cause of hospitalization of pregnant women (1). Although the incidence and burden of preterm birth are relatively clear, the causes of preterm labor are not well understood (2).

Original languageEnglish
Title of host publicationPrinciples of Pharmacogenetics and Pharmacogenomics
PublisherCambridge University Press
Pages202-216
Number of pages15
ISBN (Print)9781139051194, 9780521885379
DOIs
StatePublished - Jan 1 2012

Fingerprint

Obstetrics
Premature Obstetric Labor
Pharmacogenetics
Drug therapy
Premature Birth
Personnel
Pregnancy
Drug Therapy
Pregnancy Complications
Live Birth
Therapeutics
Medical problems
Health care
Developed Countries
Pharmaceutical Preparations
Nausea
Vomiting
Pregnant Women
Hospitalization
Fetus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Haas, D., & Renbarger, J. (2012). Pharmacogenetics of obstetric therapeutics. In Principles of Pharmacogenetics and Pharmacogenomics (pp. 202-216). Cambridge University Press. https://doi.org/10.1017/CBO9781139051194.021

Pharmacogenetics of obstetric therapeutics. / Haas, David; Renbarger, Jamie.

Principles of Pharmacogenetics and Pharmacogenomics. Cambridge University Press, 2012. p. 202-216.

Research output: Chapter in Book/Report/Conference proceedingChapter

Haas, D & Renbarger, J 2012, Pharmacogenetics of obstetric therapeutics. in Principles of Pharmacogenetics and Pharmacogenomics. Cambridge University Press, pp. 202-216. https://doi.org/10.1017/CBO9781139051194.021
Haas D, Renbarger J. Pharmacogenetics of obstetric therapeutics. In Principles of Pharmacogenetics and Pharmacogenomics. Cambridge University Press. 2012. p. 202-216 https://doi.org/10.1017/CBO9781139051194.021
Haas, David ; Renbarger, Jamie. / Pharmacogenetics of obstetric therapeutics. Principles of Pharmacogenetics and Pharmacogenomics. Cambridge University Press, 2012. pp. 202-216
@inbook{540e60fbe4494d4aaccdbd40130f9670,
title = "Pharmacogenetics of obstetric therapeutics",
abstract = "Obstetric pharmacology, in many respects, is still in its infancy. Because of valid concerns about the safety of drugs to both the mother and developing fetus, not as much data exist for drugs in pregnancy. There is also a distinct paucity of data regarding pharmacogenetics in pregnancy. At this time, many of the potential pharmacogenetic applications to pregnancy drug therapy are theoretical. This chapter summarizes the drug therapy for five of the major pregnancy conditions/complications, along with a brief discussion of potential pharmacogenetic or individualized pharmacotherapy applications for each. These conditions are preterm labor, depression, diabetes, the nausea and vomiting of pregnancy (NVP), and hypertension. Preterm Labor Preterm birth is the leading cause of morbidity and mortality in newborns in the United States. More than 12.5 percent of all live births are preterm, accounting for a large amount of health care spending for infants. The number of preterm births in the United States, as well as in many other industrialized countries, continues to rise. Preterm labor is the most common cause of hospitalization of pregnant women (1). Although the incidence and burden of preterm birth are relatively clear, the causes of preterm labor are not well understood (2).",
author = "David Haas and Jamie Renbarger",
year = "2012",
month = "1",
day = "1",
doi = "10.1017/CBO9781139051194.021",
language = "English",
isbn = "9781139051194",
pages = "202--216",
booktitle = "Principles of Pharmacogenetics and Pharmacogenomics",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Pharmacogenetics of obstetric therapeutics

AU - Haas, David

AU - Renbarger, Jamie

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Obstetric pharmacology, in many respects, is still in its infancy. Because of valid concerns about the safety of drugs to both the mother and developing fetus, not as much data exist for drugs in pregnancy. There is also a distinct paucity of data regarding pharmacogenetics in pregnancy. At this time, many of the potential pharmacogenetic applications to pregnancy drug therapy are theoretical. This chapter summarizes the drug therapy for five of the major pregnancy conditions/complications, along with a brief discussion of potential pharmacogenetic or individualized pharmacotherapy applications for each. These conditions are preterm labor, depression, diabetes, the nausea and vomiting of pregnancy (NVP), and hypertension. Preterm Labor Preterm birth is the leading cause of morbidity and mortality in newborns in the United States. More than 12.5 percent of all live births are preterm, accounting for a large amount of health care spending for infants. The number of preterm births in the United States, as well as in many other industrialized countries, continues to rise. Preterm labor is the most common cause of hospitalization of pregnant women (1). Although the incidence and burden of preterm birth are relatively clear, the causes of preterm labor are not well understood (2).

AB - Obstetric pharmacology, in many respects, is still in its infancy. Because of valid concerns about the safety of drugs to both the mother and developing fetus, not as much data exist for drugs in pregnancy. There is also a distinct paucity of data regarding pharmacogenetics in pregnancy. At this time, many of the potential pharmacogenetic applications to pregnancy drug therapy are theoretical. This chapter summarizes the drug therapy for five of the major pregnancy conditions/complications, along with a brief discussion of potential pharmacogenetic or individualized pharmacotherapy applications for each. These conditions are preterm labor, depression, diabetes, the nausea and vomiting of pregnancy (NVP), and hypertension. Preterm Labor Preterm birth is the leading cause of morbidity and mortality in newborns in the United States. More than 12.5 percent of all live births are preterm, accounting for a large amount of health care spending for infants. The number of preterm births in the United States, as well as in many other industrialized countries, continues to rise. Preterm labor is the most common cause of hospitalization of pregnant women (1). Although the incidence and burden of preterm birth are relatively clear, the causes of preterm labor are not well understood (2).

UR - http://www.scopus.com/inward/record.url?scp=84925595377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925595377&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139051194.021

DO - 10.1017/CBO9781139051194.021

M3 - Chapter

SN - 9781139051194

SN - 9780521885379

SP - 202

EP - 216

BT - Principles of Pharmacogenetics and Pharmacogenomics

PB - Cambridge University Press

ER -